TY - JOUR
T1 - Current progress in dengue vaccines
AU - Wan, Shu Wen
AU - Lin, Chiou Feng
AU - Wang, Shuying
AU - Chen, Yu Hung
AU - Yeh, Trai Ming
AU - Liu, Hsiao Sheng
AU - Anderson, Robert
AU - Lin, Yee Shin
N1 - Funding Information:
This work was supported by Grants NSC101-2325-B-006-006, NSC101-2321-B-006-002 and NSC101-2321-B-006-031 from the National Science Council, Taiwan, and DOH102-TD-B-111-002 from Multidisciplinary Center of Excellence for Clinical Trial and Research, Department of Health, Taiwan.
PY - 2013
Y1 - 2013
N2 - Dengue is one of the most important emerging vector-borne viral diseases. There are four serotypes of dengue viruses (DENV), each of which is capable of causing self-limited dengue fever (DF) or even life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The major clinical manifestations of severe DENV disease are vascular leakage, thrombocytopenia, and hemorrhage, yet the detailed mechanisms are not fully resolved. Besides the direct effects of the virus, immunopathological aspects are also involved in the development of dengue symptoms. Although no licensed dengue vaccine is yet available, several vaccine candidates are under development, including live attenuated virus vaccines, live chimeric virus vaccines, inactivated virus vaccines, and live recombinant, DNA and subunit vaccines. The live attenuated virus vaccines and live chimeric virus vaccines are undergoing clinical evaluation. The other vaccine candidates have been evaluated in preclinical animal models or are being prepared for clinical trials. For the safety and efficacy of dengue vaccines, the immunopathogenic complications such as antibody-mediated enhancement and autoimmunity of dengue disease need to be considered.
AB - Dengue is one of the most important emerging vector-borne viral diseases. There are four serotypes of dengue viruses (DENV), each of which is capable of causing self-limited dengue fever (DF) or even life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The major clinical manifestations of severe DENV disease are vascular leakage, thrombocytopenia, and hemorrhage, yet the detailed mechanisms are not fully resolved. Besides the direct effects of the virus, immunopathological aspects are also involved in the development of dengue symptoms. Although no licensed dengue vaccine is yet available, several vaccine candidates are under development, including live attenuated virus vaccines, live chimeric virus vaccines, inactivated virus vaccines, and live recombinant, DNA and subunit vaccines. The live attenuated virus vaccines and live chimeric virus vaccines are undergoing clinical evaluation. The other vaccine candidates have been evaluated in preclinical animal models or are being prepared for clinical trials. For the safety and efficacy of dengue vaccines, the immunopathogenic complications such as antibody-mediated enhancement and autoimmunity of dengue disease need to be considered.
UR - http://www.scopus.com/inward/record.url?scp=84878818110&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878818110&partnerID=8YFLogxK
U2 - 10.1186/1423-0127-20-37
DO - 10.1186/1423-0127-20-37
M3 - Review article
C2 - 23758699
AN - SCOPUS:84878818110
SN - 1021-7770
VL - 20
JO - Journal of biomedical science
JF - Journal of biomedical science
IS - 1
M1 - 37
ER -